PerkinElmer to acquire BioLegend for $5.25B; expects $0.30 adjusted EPS accretion in first full year

REVVITY, INC.

Purchase price ~$5.25B; 59.5% cash and 40.5% stock at $156.3561/share.
BioLegend estimated 2022 revenues ~$380M with mid-teens-plus growth.
Expected $0.30 adjusted EPS accretion in 1st full year, >$0.50 in 2nd year.
Revenue synergies expected $100M annually by 5th year post-close; no significant cost synergies planned.
Bridge financing of $3.3B committed by Goldman Sachs; no financing condition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.